Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

What is Cancer?

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.

ESMO open·2022

Same author

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update.

Case reports in oncological medicine·2019

Same author

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

Cancer chemotherapy and pharmacology·2018

Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Circulating cancer cells.

¹Department of Medical Oncology, University Hospital of Heraklion, Laboratory of Tumor Biology, Medical School, University of Crete, Greece. mavrudis@med.uoc.gr

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|October 15, 2010

Summary

This summary is machine-generated.

Detecting circulating tumor cells (CTCs) in blood offers personalized cancer risk assessment. Standardized methods are crucial for reliable prognosis and guiding targeted therapies, improving patient outcomes.

More Related Videos

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Published on: June 15, 2012

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Published on: June 15, 2012

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

Area of Science:

Oncology
Cancer Biology
Molecular Diagnostics

Background:

Circulating tumor cells (CTCs) are detectable in various cancer stages using antibody-based or molecular assays.
Detection and quantification of CTCs often correlate with unfavorable prognosis, offering risk assessment beyond TNM staging.
Heterogeneity of CTCs and variability in detection methods necessitate standardization and cross-validation.

Purpose of the Study:

To highlight the potential of CTC detection for individualized risk assessment in cancer patients.
To emphasize the need for standardized and validated CTC detection methodologies.
To explore the utility of CTC phenotyping and characterization for predicting treatment response and guiding therapy.

Main Methods:

Review of current antibody-based and molecular methods for CTC detection.
Analysis of studies linking CTC detection and quantification to patient prognosis.
Discussion of pilot studies on CTC phenotyping for targeted therapy response prediction.

Main Results:

CTC detection is linked to unfavorable prognosis and offers risk stratification beyond TNM staging.
Methodological discrepancies in CTC detection yield discordant results, underscoring the need for standardization.
CTC phenotyping shows promise in predicting response to targeted therapies.

Conclusions:

Standardized CTC detection and characterization are essential for reliable prognosis and personalized cancer therapy.
CTCs can serve as a real-time tumor biopsy for tailoring treatment strategies.
Prospective randomized studies are needed to validate CTC assessment and monitoring for improved clinical outcomes.